AllDocs -> cancers

Lung Cancer , Cardiopulmonary Mortality, and Long-term Exposure to Fine Particulate Air Pollution Vol. 287 No. 9, March 6, 2002 C. Arden Pope III, PhD; Richard T. Burnett, PhD; Michael J. Thun, MD; Eugenia E. Calle, PhD; Daniel Krewski, PhD; Kazuhiko Ito, PhD; George D. Thurston, ScD Context Associations have been found between day-to-day particulate air pollution and increased risk of various adverse health outcomes, including cardiopulmonary mortality. However, studies of health effects of long-term particulate air pollution have been less conclusive. Objective To assess the relationship between long-term exposure to fine particulate air pollution and all-cause, lung cancer , and cardiopulmonary mortality. Design, Setting, and Participants Vital status and cause of death data were collected by the American Cancer Society as part of the Cancer Prevention II study, an ...

The Marie Keating Foundation A long-term goal of the Foundation is to offer Information and Awareness in all areas of cancer . This service will be provided to everyone through the Mobile Units with information leaflets and other promotional materials, sponsored events, seminars and on-site visits to the work place and education facilities for all ages. Publicity campaigns will be run and the Foundation’s website www.mariekeating.com will offer updated information and links to other appropriate websites. The Foundation also intends to offer medical and nursing scholarships in the future. The Marie Keating Foundation would like to thank BreastCheck, Europa Donna, the Irish Cancer Society, Action Cancer – Northern Ireland, and health care professionals specialising in cancer care for their cooperation and support. The Foundation is made up of: The Board ...

Guidance on Commissioning Cancer Services Improving Outcomes in Lung Cancer The Manual G O O D P R A C T I C E Page 2 Contact Point Triona Norman NHS Executive Health Services Directorate Wellington House London SE1 8UG Further copies from Department of Health PO Box 410 Wetherby LS23 7LL Catalogue number 97CC122 Date of issue June 1998 G O O D P R A C T I C E Examples of and advice on good practice Purpose of this document This booklet is intended to help those planning and commissioning cancer services, in partnership with local hospitals and the community to improve the quality of care for people with lung cancer or those at higher risk of developing the disease. It is intended to support the ongoing implementation of the ...

lung cancer Lung Cancer You?ve been diagnosed. You?re NOT alone. There ARE options! Becoming pro-active in your care may increase your chances of SURVIVAL! YOU?VE BEEN DIAGNOSED, NOW WHAT? SOME THINGS TO ASK YOUR DOCTOR What type of lung cancer do I have? What stage is my cancer ? Has my cancer spread to other parts of my body? What are my treatment options? Am I a candidate for radiation or surgery? Is this facility trained and familiar with my type of lung cancer ? RESEARCH: Find out everything you can about your lung cancer . There are excellent resources online about L/C, hospitals, specialists, new treatments options, chemotherapy, radiation, RFA, Gamma Knife, PCI and the latest in clinical trials across the country. DO NOT let the statistics scare you. Put them on a shelf ...

Bounding Analysis of Lung Cancer Risks Using Imprecise Probabilities * M INH H A -D UONG Centre National de la Recherche Scientifique, France E LIZABETH C ASMAN Carnegie Mellon University, USA M. G RANGER M ORGAN Carnegie Mellon University, USA Abstract For cancers with more than one risk factor, the sum of probabilistic estimates of the number of cancers attributable to each individual factor may exceed the total number of cases observed when uncertainties about exposure and dose-response for some factors is high. In this study we outline a method to bound the fraction of lung cancer fatalities not attributed to specific well- studied causes in which available data and expert judgment are used to at- tribute portions of the observed lung cancer mortality ...

Lung Cancer Education and Support Group For : Adult Patients, Family, Caregivers and Friends Time : 10:00am-Noon When : The 4 th Friday of each month, Place : Saint Louis University Cancer Center Cost : Free Topics : Come and listen to professionals speak on topics related to lung cancer Light refreshments served RSVP: Teresa Dunleavy, RN, BSN, OCN 314-268-7015 Page 2 Education and Support Group WHO: Adult patients, family, and friends coping with leukemia , lymphomas , multiple myelomas , and other blood related cancers . When: 2 nd Monday of each Month Where: 1 ...

T his issue of Lung Cancer Frontiers features selected manuscripts from a recent conference conducted in Germany, along with selected abstracts from the peer reviewed literature and some additional editorial comments about early diagnosis of lung cancer . The editors hope you will find this year’s final issue of Lung Cancer Frontiers both interesting and stimulating. Introduction to the John Nakhosteen “Retirement” Symposium. By: Thomas L. Petty, M.D., Editor T he following manuscripts were selected from a special symposium held in Bochum Germany to commemorate the retirement of the Chief of the Augusta Teaching Hospital Program in Pulmonology. Professor John Nakhosteen has been a leader in pulmonology with special emphasis in bronchology in Europe for many years. It is appropriate to include the brief review ...

lung cancer LUNG CANCER AZIAH AHMAD MAHAYIDDIN MBBCh (Hons), Dip.Tho.Med., MRCP(UK), FCCP, FAMM, FRCP. Agenda Cancer Burden Frequency Sex Differences Ethnic variation Age variation AND wherever possible comparing the findings with international data LUNG CANCEr -Malignancy of trachea, bronchus and lungsreported from the period from 1st Jan 2002-31st December 2002 -And the classification in this report is primarily topographical i.e site and not morphological. And do not include Larynx and pleura LUNG CANCER ...

1 Of Mice Men and ( Lung ) Cancer Aravind Subramanian, Alejandro Sweet-Cordero, and Sayan Mukherjee The Problem: Validating a mouse model of lung cancer at the molecular level. Given DNA expres- sion data from a mouse model of lung adenocarcinoma, among a variety of human cancer expression data state the one most similar to the mouse model of adenocarcinoma. In addition, examine whether mutational effects in the human data might be related to the mouse model. Motivation: Animal models of human disease serve are basic to our understanding and attempts at treatment of disease. Mouse models have been used extensively to study cancer . However, there has never been a genomic or molecular validation of the various mouse models developed. We performed the first molecular validation of a mouse model. The mouse model we focussed on is a mouse model of adenocarcinoma. Previous Work: ...

– NEWS RELEASE – For Immediate Release Tuesday, November 26, 2002 ONTARIO’S LEADING CAUSE OF CANCER DEATH NEEDS PRIORITY ATTENTION Lung cancer patients need coordinated approach for early detection and multidisciplinary care TORONTO, ON – At least 16 people will die of lung cancer in Ontario today. The Cancer Advocacy Coalition of Canada (CACC) today urges Ontario MPPs to give lung cancer the attention it needs in order to improve survival rates. Lung cancer is the leading cause of cancer deaths in this province but lacks a coordinated strategy for early detection and multidisciplinary care, including research, referral protocols, best practices and education for physicians and patients. “Nobody deserves to suffer from such a devastating illness without access to the same standards of health care provided to patients of other cancers,” said Pat ...

lung cancer Understanding Lung Cancer & New Directions in Research and Treatment Options David P. Carbone, M.D., Ph.D. We = re going to have several physicians speak today. I = m going to start out talking about lung cancer in general and some of the things we = re doing. This is not really about the lung cancer SPORE grant but rather about lung cancer and how it affects patients. The SPORE grant is just a mechanism to use to try to help lung cancer patients. Dr. Choy is going to talk to us a little bit about the radiation aspects of lung cancer and some other issues. This afternoon Dr. Sandler is going to talk to you about clinical trials that we = re doing. So I = m not going to focus on specific clinical trials, I = m just going to give you brief summaries. This is my message for my talk and I = m going to start out ...

he Vanderbilt-Ingram Cancer Center has signed on as an organizational partner for Lung Cancer Awareness Month with the Alliance for Lung Cancer Advocacy, Support and Education (ALCASE) to build awareness about the leading cause of cancer deaths in the United States for both men and women. Vanderbilt-Ingram is one of the leading health institutions partnering with ALCASE in their education campaign which culminates every November, Lung Cancer Awareness Month. ALCASE is a nonprofit organization solely dedicated to helping people at risk for or living with lung cancer . They offer a variety of programs and services includ- ing: • A toll-free information hotline where patients can learn about their disease and its treatments 1-800-298-2436 • A comprehensive Web site with infor- mation about lung ...

Lung Cancer News Tips from Duke Comprehensive Cancer Center At the Duke Comprehensive Cancer Center, members of the Thoracic Oncology Program are working to improve the treatment and care of patients with lung cancer , the nation's leading cancer killer in both men and women. In 2000, lung cancer is expected to claim 156,900 lives in the United States. While the death rate from lung cancer has increased dramatically since cigarette smoking became popular in the 1930s, in recent years the death rate in men has begun to decrease and in women it has become stable, according to the American Cancer Society. November is Lung Cancer Awareness Month, and below are a few of the cutting-edge resources available at Duke. PATIENTS HAPPY WITH PDT -- Certain patients with lung cancer at Duke Comprehensive Cancer Center can choose a less harsh treatment to destroy their tumors -- ...

lung cancer Association of Indoor Radon Level and Lung Cancer in Saraphi District, Chiang Mai Assoc. Prof. Dr.Phongtape Wiwatanadate, et al. Department of Community Medicine Faculty of Medicine Chiang Mai University E-mail: pwiwata@mail.med.cmu.ac.th Introduction Among cancers, lung cancer is the leading cause of death after liver cancer in Thai people. The highest incidence was found in the Northern region. The average annual age-standardized incidence in Chiang Mai of male during 1988-1991 was 49.8 per 100,000 and that of female was 37.4 per 100,000. Introduction Smoking has been found to be the main cause of lung cancer but it was not significant risk factor in Chiang Mai. Radon exposure was attributed to 5,000 to 20,000 lung cancer deaths a year in the United States. Indoor radon concentrations ...

VOL 9/NO 4, OCT/DEC 2003 • www.ijoeh.com Special Contribution • 397 I thank Dr. Boffetta and co- authors 1 for taking the trouble to answer my critique of their study on lung cancer among man-made vit- reous fibers (MMVF) production workers, 2 a critique that I e-mailed to each one of them as early as Sep- tember–October 2001. (Regret- tably, I never received any response to this attempt to engage Dr. Bof- fetta and co-workers in an informal scientific discussion of their study.) In their letter to the editor, 1 Dr. Boffetta and co-authors declare their surprise that my critique 3 was published in the present journal. Some background information is needed to elucidate why things happened that way: When Dr. Boffetta and co-work- ers first published their study in ...

A D V A N C E D Non-Small Cell Lung Cancer I MPLEMENTING T REATMENT A DVANCES IN C LINICAL P RACTICE Friday, April 30, 2004 • Breakfast Program • 6:00 am – 8:00 am Marriott Grand Ballroom A-E • Anaheim, CA Page 2 A subsidiary of the Oncology Nursing Society This educational program has been developed and produced by Oncology Education Services, Inc. (OES), through an unrestricted educational grant from Lilly Oncology. The opinions expressed in this presentation are those of the participating faculty. It should not be inferred or assumed that they are expressing the views of OES or any of the manufacturers of pharmaceuticals mentioned in the program. Copyright © 2004 Oncology Education Services, Inc. All rights reserved. No part of this publication ...

New and Emerging Technology Briefing Breath test for lung cancer screening January 2004 Horizon Scanning Review Early assessments of new or emerging technologies contain time-limited information and should be used with due caution. Not to be used for commercial purposes National Horizon Scanning Centre Page 2 National Horizon Scanning Centre Breath test for lung cancer January 2004 2 Breath test for lung cancer screening Summary Breath test for lung cancer is a non-invasive test that measures volatile organic compounds (VOCs) in the breath and predicts the probability of lung cancer in an individual. In a group of 178 people who had undergone bronchoscopy for the evaluation of symptoms of lung cancer , analysis of breath ...

Table of Contents Stakeholder Insight: Lung Cancer DMHC1906 © Datamonitor (Published 12/2003) Page 16 This report is a licensed product and is not to be photocopied TABLE OF CONTENTS Richard Faint – Director of Oncology 2 CHAPTER 1 EXECUTIVE SUMMARY 3 Scope of the analysis 3 Datamonitor insight into the lung cancer market 4 Cisplatin plus Campto (irinotecan) is the gold-standard regimen for extensive SCLC in Japan, based on the results of a Japanese trial. Physicians in the US and Europe are generally skeptical of the regimen and it will not see a wide uptake until the results are replicated in a Western clinical trial 4 Third-generation cytotoxics, such as gemcitabine, vinorelbine and paclitaxel, commonly used for NSCLC, are increasingly being prescribed to SCLC patients. Having reached an efficacy ...

Brochure More information from http://www.researchandmarkets.com/reports/951 Drugs of Tomorrow 2001: Lung Cancer Description: Lung Cancer is currently served by cytotoxic agents, however, survival rates have not improved over the last decade. With a high level of unmet need, innovative products are expected to achieve high clinical uptake. In particular, AstraZenecas Iressa will make considerable impact in the lung cancer market in the next five years. Datamonitors ‘Drugs of Tomorrow 2002: Lung Cancer -Iressa Driving The Pipeline Market’ provides in-depth analysis of the key pipeline drugs for lung cancer in the seven major pharmaceutical markets including: US, Japan, UK, France, Germany, Spain, Italy. You gain access to: • Accurate and up-to-date R&D information on the focus and direction of the major players in the lung cancer market • Identification ...

Lung Cancer Lung Cancer Dr. Tony Dr. Tony Reiman Reiman Pharmacy 589 Pharmacy 589 November 2003 November 2003 Page 2 Objectives Objectives Epidemiology, Etiology, Prevention, Screening Epidemiology, Etiology, Prevention, Screening Pathophysiology, Presentation Pathophysiology, Presentation Diagnosis, Investigations Diagnosis, Investigations Non Non - - small cell lung cancer small cell lung cancer Staging, Treatment, prognosis Staging, Treatment, prognosis Small cell lung cancer Small cell lung cancer Staging, Treatment, prognosis Staging, Treatment, prognosis Novel therapies, supportive therapies Novel therapies, supportive therapies ...

12531 12546 12501 12522 12581 12545 12533 12582 12570 12601 12508 12524 12563 12590 12538 12578 12594 12592 12514 12580 12567 12583 12571 10516 10512 10509 10524 10537 10541 10579 12540 12564 12569 12572 12603 Lung Cancer Incidence by ZIP Code Males, Dutchess and Putnam Counties, New York State 1993-1997 within 15% of expected 15 to 50% below expected more than 50% below expected more than 100% above expected very sparse data 15 to 49% above expected Comparison of individual ZIP Codes with expected incidence 50% to 100% above expected D U T C H E S S P U T N A M

13037 13032 13421 13425 13480 13355 13314 13491 13408 13310 13030 13476 13035 13061 13122 13334 13402 13409 13485 Lung Cancer Incidence by ZIP Code Males, Madison County, New York State 1993-1997 within 15% of expected 15 to 50% below expected more than 50% below expected more than 100% above expected very sparse data 15 to 49% above expected Comparison of individual ZIP Codes with expected incidence 50% to 100% above expected Areas of elevated incidence not likely due to chance 50-100% above expected more than 100% above expected 13460 13052 13072 13332 13346 13082

14810 14821 14812 14879 14815 14840 14837 14870 14814 14830 14839 14820 14819 14823 14807 14843 14806 14897 14898 14858 14871 14801 14885 14873 14512 14826 14437 14572 14809 Lung Cancer Incidence by ZIP Code Males, Steuben County, New York State 1993-1997 within 15% of expected 15 to 50% below expected more than 50% below expected more than 100% above expected very sparse data 15 to 49% above expected Comparison of individual ZIP Codes with expected incidence 50% to 100% above expected Areas of elevated incidence not likely due to chance 50-100% above expected more than 100% above expected

lung cancer BRITISH THORACIC SOCIETY LUNG CANCER WORKING PARTY CONSENSUS STATEMENT ON SPECIALISED DIAGNOSTIC & THERAPEUTIC BRONCHOSCOPY Introduction: Specialised bronchoscopic techniques are available for diagnosis and for treatment of endobronchial disease. Principal treatment modalities are de-bulking techniques (electrocautery; forceps removal; laser; cryotherapy), photodynamic therapy, stenting, and brachytherapy. These modalities can be used alone or in combination to attempt cure or for symptom palliation, and can be combined with external beam radiotherapy for cancer , or prior to definitive surgery. Fluorescence Bronchoscopy (FB): Examples of the systems in use are laser imaging fluorescence endoscopy (LIFE); the Stortz D-light system; and the PENTAX SAFE 1000 system. Endobronchial ...

11.10.1999 11.10.1999 11.10.1999 11.10.1999 Study Design in the ATBC Study Study Design in the ATBC Study Two factorial design with four intervention groups: • Alpha-tocopherol (50 mg) • Beta-carotene (20 mg) • Both (50 mg + 20 mg) • Placebo Two factorial design with four intervention groups: • Alpha-tocopherol (50 mg) • Beta-carotene (20 mg) • Both (50 mg + 20 mg) • Placebo Page 2 11.10.1999 11.10.1999 11.10.1999 11.10.1999 Prospective Studies on Intake of Prospective Studies on Intake of Beta-carotene and Vitamin A and the Beta-carotene and Vitamin A and the Subsequent Risk of Lung Cancer Subsequent Risk of Lung Cancer Study Follow-up years Study Cohort Cases N ...

Philadelphia, PA www.fccc.edu ? FACULTY ? Melvyn Goldberg, MD Vice Chairman, Surgical Oncology Chief, Thoracic Surgical Oncology ? Fox Chase Cancer Center Corey J. Langer, MD, FACP Medical Director, Thoracic Medical Oncology ? Fox Chase Cancer Center Benjamin Movsas, MD Vice Chairman, Radiation Oncology ? Fox Chase Cancer Center Michael Unger, MD, FACP, FCCP Director, Pulmonary Cancer Detection and Prevention Program Director, Pulmonary Endoscopy and High-Risk Lung Cancer Program ? Fox Chase Cancer Center STATEMENT OF THE FOX CHASE CANCER CENTER DISCLOSURE POLICY It is the policy of Fox Chase Cancer Center to insure that all sponsored continuing medical education activities are independently designed and produced, relative ...

lung cancer Lung Cancer Epidemiology, diagnosis and treatment Estimated new cases (incidence) and deaths (mortality) worldwide for the 15 most common cancers, 2000 Thousands Lung Breast Colon/rectum Stomach Liver Prostate Cervix uteri Oesophagus Bladder Non-Hodgkin’s lymphoma Oral cavity Leukaemia Pancreas Ovary Kidney Males Females 1200 1000 800 600 400 200 Parkin et al 2001 Age-adjusted lung cancer death rates, USA (1930-1998) and the influence of smoking 80 60 40 20 0 1930 1940 1950 ...